Element Solutions Inc. Common Stock vs Novartis AG — how do they compare? Element Solutions Inc. Common Stock trades at $36.56 (market cap $9.06B), while Novartis AG trades at $142.74 (market cap $268.57B). The key difference: Novartis AG is far larger — about 29.6× Element Solutions Inc. Common Stock's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Element Solutions Inc. Common Stock for 0 Days and Novartis AG for 82 Days on average.
| ESI | NVS | |
|---|---|---|
Market Cap | $9.06B | $268.57B |
Volume | 2,417,180 | 1,532,573 |
Sector | Basic Materials | Health |
52-Week High | $49.09 | $168.62 |
52-Week Low | $22.99 | $121.80 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $10.99B | $309.89B |
Dividend Yield | 0.86% | 3.31% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Element Solutions provides specialty chemical products and technical services. Its solutions support electronics, communications, automotive systems, industrial surface finishing, and offshore energy.
Read more on ESI →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →